Clinical trial to test two treatments for vitiligo sufferers

   
   
Vitiligo
16 Jun 2016 14:18:49.673

PA141/16

People who suffer from the skin condition ‘vitiligo’ are being encouraged to take part in a clinical trial led by The University of Nottingham’s Centre of Evidence Based Dermatology and the Nottingham Clinical Trials Unit

Vitiligo is a condition that affects the pigmentation of the skin, causing white patches to appear on the skin of people of all ages and skin colours. It affects up to 1 per cent of the population worldwide and up to now, treatment has been limited and the effectiveness of some treatments has not been tested in large studies. 

The HI-Light Vitiligo Trial, funded by the National Institute for Health Research (NIHR)’s Health Technology Assessment Programme, aims to test two commonly used treatments – steroid cream and light treatment using a hand-held narrow band UVB light. The research team is looking for 440 children (five years and above) and adults with vitiligo across the UK to take part in the study, using treatments for nine months and then being followed up to assess long term treatment effects. 

Click here for full story

Volunteers will be given one of three combinations of treatment:

·         A steroid cream and UVB light treatment

·         A placebo cream (containing no steroid) and UVB light treatment

·         A steroid cream and a dummy light (bulb that does not emit UVB light) 

Participation in the study will involve five hospital visits over nine months, but the treatment will be mainly carried out by the patient or carer in their own time at home.  Patients will also be asked to complete a diary about their vitiligo and some questionnaires. 

Leading the study, Dr Jonathan Batchelor said: “We are looking for people who have at least one patch of vitiligo that has appeared or worsened over the past year. Although steroid cream and light treatment are commonly used to treat vitiligo, we don’t know how well they work and whether they work together. Also hand held light-therapy units are not available on the NHS at the moment, so if we find that they work well they could become a home-based NHS treatment option in the future.” 

Professor Kim Thomas from the University’s Centre of Evidence Based Dermatology added: “Vitiligo is not painful, but the white patches that appear on the skin can have a devastating impact on patients, especially for those with dark skin. It can be particularly upsetting when the vitiligo starts to spread rapidly for no apparent reason. Many patients are keen to find effective treatments for their vitiligo, but the options currently available in the UK are quite limited. We hope this study will provide better evidence to support the use of one or both of these treatments in the future.” 

Around 15 hospitals around England, Scotland and Wales are involved in the trial.  More information about the trial and details on how to apply to take part can be found here including a training video for participants. 

The HI-Light Study is being coordinated by Nottingham Clinical Trials Unit at The University of Nottingham. The study is funded by the Health Technology Assessment Programme of NIHR.

— Ends —

Our academics can now be interviewed for broadcast via our Media Hub, which offers a Globelynx fixed camera and ISDN line facilities at University Park campus. For further information please contact a member of the Communications team on +44 (0)115 951 5798, email mediahub@nottingham.ac.uk or see the Globelynx website for how to register for this service.

For up to the minute media alerts, follow us on Twitter

Notes to editors: The University of Nottingham has 43,000 students and is ‘the nearest Britain has to a truly global university, with a “distinct” approach to internationalisation, which rests on those full-scale campuses in China and Malaysia, as well as a large presence in its home city.’ (Times Good University Guide 2016). It is also one of the most popular universities in the UK among graduate employers and was named University of the Year for Graduate Employment in the 2017 The Times and The Sunday Times Good University Guide. It is ranked in the world’s top 75 by the QS World University Rankings 2015/16, and 8th in the UK for research power according to the Research Excellence Framework 2014. It has been voted the world’s greenest campus for four years running, according to Greenmetrics Ranking of World Universities.

Impact: The Nottingham Campaign, its biggest-ever fundraising campaign, is delivering the University’s vision to change lives, tackle global issues and shape the future. More news…

Story credits

More information is available from Garry Meakin (Trial Manager) or Jen White (Trial Coordinator), Nottingham Clinical Trials Unit, University of Nottingham on +44 (0)115 823 1586hilight@nottingham.ac.uk 

EmmaRayner2

Emma Rayner - Media Relations Manager

Email: emma.rayner@nottingham.ac.uk Phone: +44 (0)115 951 5793 Location: University Park

Additional resources

No additional resources for this article

Media Relations - External Relations

The University of Nottingham
C Floor, Pope Building (Room C4)
University Park
Nottingham, NG7 2RD

telephone: +44 (0) 115 951 5798
email: communications@nottingham.ac.uk